share_log

康方生物：有關收購康融東方股權的關連交易

AKESO: CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF EQUITY INTEREST IN AD PHARMACEUTICALS

香港交易所 ·  Feb 8 18:30
Summary by Moomoo AI
康方生物科技（開曼）有限公司（「康方生物」）於2024年2月8日宣布，其間接全資附屬公司中山康方生物醫藥有限公司（「買方」）與東瑞生物投資發展（亞洲）有限公司（「賣方」）簽訂股權轉讓協議，購買賣方持有的康融東方35%股權。該交易使康融東方成為康方生物的間接全資附屬公司。交易代價為人民幣267,387,280.82元，預計將使用集團內部資源支付。康融東方主要從事創新藥物產品研發，包括已提交新藥上市申請的伊努西單抗（AK102）及處於II期臨床試驗的普絡西單抗（AK109）。康方生物表示，此次收購有助於未來商業化發展和產能利用，並能發揮集團在研發、生產和商業化方面的成本和協同效應。董事會認為交易條款公平合理，並符合公司及股東整體利益。
康方生物科技（開曼）有限公司（「康方生物」）於2024年2月8日宣布，其間接全資附屬公司中山康方生物醫藥有限公司（「買方」）與東瑞生物投資發展（亞洲）有限公司（「賣方」）簽訂股權轉讓協議，購買賣方持有的康融東方35%股權。該交易使康融東方成為康方生物的間接全資附屬公司。交易代價為人民幣267,387,280.82元，預計將使用集團內部資源支付。康融東方主要從事創新藥物產品研發，包括已提交新藥上市申請的伊努西單抗（AK102）及處於II期臨床試驗的普絡西單抗（AK109）。康方生物表示，此次收購有助於未來商業化發展和產能利用，並能發揮集團在研發、生產和商業化方面的成本和協同效應。董事會認為交易條款公平合理，並符合公司及股東整體利益。
Kangfang Biotechnology (Cayman) Co., Ltd. (“Kangfang Biotech”) announced on 8 February 2024 that its wholly-owned subsidiary Zhongshan Kangfang Biopharmaceuticals Limited (the “Buyer”) and Dongrai Bio-Investment Development (Asia) Limited (the “Seller”) entered into an equity transfer agreement, the Buyer Owned 35% shareholding in Regenerational Oriental. The transaction makes Hong Kong Oriental an indirect wholly-owned subsidiary of Kangfang Bios. The transaction cost RMB267,387,280.82 and is expected to be paid using the Group's internal resources. Hong Kong Eastern is primarily engaged in the development of innovative drug products, including Inuccinate (AK102), which has submitted a new marketing application, and Placetic Anti (AK109), which is in Phase II clinical trials. Kangfang Bio said that the acquisition will contribute to future commercialisation and capacity utilisation, and will leverage the Group's cost and synergies in R&D, production and commercialisation. The Board considers that the terms of the transaction are fair and reasonable and in the overall interests of the Company and its shareholders.
Kangfang Biotechnology (Cayman) Co., Ltd. (“Kangfang Biotech”) announced on 8 February 2024 that its wholly-owned subsidiary Zhongshan Kangfang Biopharmaceuticals Limited (the “Buyer”) and Dongrai Bio-Investment Development (Asia) Limited (the “Seller”) entered into an equity transfer agreement, the Buyer Owned 35% shareholding in Regenerational Oriental. The transaction makes Hong Kong Oriental an indirect wholly-owned subsidiary of Kangfang Bios. The transaction cost RMB267,387,280.82 and is expected to be paid using the Group's internal resources. Hong Kong Eastern is primarily engaged in the development of innovative drug products, including Inuccinate (AK102), which has submitted a new marketing application, and Placetic Anti (AK109), which is in Phase II clinical trials. Kangfang Bio said that the acquisition will contribute to future commercialisation and capacity utilisation, and will leverage the Group's cost and synergies in R&D, production and commercialisation. The Board considers that the terms of the transaction are fair and reasonable and in the overall interests of the Company and its shareholders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more